PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels

European Journal of Medical Research

Volumn 16, Issue 8, 2011, Pages 367-374

  Erbel, Christian ^a   Achenbach, J ^a   Akhavanpoor, M ^a   Dengler, T J ^a   Lasitschka, F ^a   Gleissner, C A ^a   Bea, F ^a   Katus, H A ^a   Szabo, G ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Atherosclerosis; Dendritic cells; Inflammation; oxLDL; PARP; T cells

Indexed keywords

CD83 ANTIGEN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INO 1001; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TRIACYLGLYCEROL; APOLIPOPROTEIN E; AUTOANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 12; OXIDIZED LOW DENSITY LIPOPROTEIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENDRITIC CELL; ENZYME INHIBITION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; RNA ANALYSIS; T LYMPHOCYTE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; AORTA ATHEROSCLEROSIS; AORTA ROOT; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; CELL INVASION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL;

EID: 80052222000     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-16-8-367     Document Type: Article

References (25)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340:115-26. (Pubitemid 29054847)
2. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6:508-19. (Pubitemid 43980523)
3. Erbel C, Sato K, Meyer FB, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol. 2007; 102:123-32. (Pubitemid 46189953)
4. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A. 1996; 93:1753-8. (Pubitemid 26079829)
5. Pacher P, Szabo C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol. 2008; 173:2-13. (Pubitemid 351947950)
6. Aldinucci A, Gerlini G, Fossati S et al. A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. J Immunol. 2007; 179:305-12. (Pubitemid 46986546)
7. Hans CP, Zerfaoui M, Naura AS, Catling A, Boulares AH. Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability. Cardiovasc Res. 2008; 78:429-39.
8. Oumouna-Benachour K, Hans CP, Suzuki Y, et al. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death. Circulation. 2007; 115:2442-50. (Pubitemid 46717967)
9. -/- mice with hyperhomocysteinemia. J Atheroscler Thromb. 2009; 16:641-53.
10. von Lukowicz T, Hassa PO, Lohmann C et al. PARP1 is required for adhesion molecule expression in atherogenesis. Cardiovasc Res. 2008; 78:158-66. (Pubitemid 351430953)
11. Erbel C, Chen L, Bea F et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in ApoE-deficient mice. J Immunol. 2009; 183:8167-75.
12. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994; 14:133-40.
13. Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998; 101:1717-25. (Pubitemid 28198502)
14. Szabo G, Bahrle S, Sivanandam V et al. Immunomodulatory effects of poly(ADP-ribose) polymerase inhibition contribute to improved cardiac function and survival during acute cardiac rejection. J Heart Lung Transplant. 2006; 25:794-804. (Pubitemid 43963381)
15. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol. 2003; 163:1117-25. (Pubitemid 37040147)
16. Hans CP, Zerfaoui M, Naura AS et al. Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content. J Pharmacol Exp Ther. 2009;329:150-8.
17. Radovits T, Lin LN, Zotkina J et al. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. Eur J Pharmacol. 2007; 564:158-66. (Pubitemid 46946861)
18. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med. 2000; 247:371-80. (Pubitemid 30180039)
19. Palinski W, Rosenfeld ME, Yla-Herttuala S et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989; 86:1372-6. (Pubitemid 19061548)
20. Tsimikas S, Bergmark C, Beyer RW et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003; 41:360-70. (Pubitemid 36164488)
21. Dotevall A, Hulthe J, Rosengren A, Wiklund O, Wilhelmsen L. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci (Lond). 2001;101:523-31.
22. Wu R, de Faire U, Lemne C, Witztum JL, Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension. 1999; 33:53-9.
23. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res. 2002; 90:E34-8.
24. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009; 131:149-50.
25. Evans D, Bode A, von der Lippe G, Beil FU, Mann WA. Cerebrovascular atherosclerosis in type III hyperlipidemia is modulated by variation in the apolipoprotein A5 gene. Eur J Med Res. 2011; 16(2):79-84.